Malignant hyperthermia or hyperpyrexia

Description

Malignant hyperthermia is a pharmacogenetic disorder of skeletal muscle that presents as a hypermetabolic response to potent volatile anaesthetic gases such as halothane, sevoflurane, desflurane and the depolarizing muscle relaxant succinylcholine, and rarely in humans, to stresses such as vigorous exercise and heat. May be caused by a mutation in the Ryonadine Receptor 1 gene.

Index terms

Malignant hyperthermia or hyperpyrexia

Exclusions from above levels

http://id.who.int/icd/entity/155258022 – Metabolic disorders
LD26.41 – Arthrogryposis multiplex congenita
05 – Endocrine, nutritional or metabolic diseases

Show allHide

18 – Complications of pregnancy, childbirth and the puerperium
19 – Certain conditions originating in the perinatal period
22 – Injury, poisoning or certain other consequences of external causes

Sibling codes

8C70 – Muscular dystrophy
8C71 – Myotonic disorders
8C72 – Congenital myopathies
8C73 – Mitochondrial myopathies
8C74 – Periodic paralyses or disorders of muscle membrane excitability
8C75 – Distal myopathies
8C76 – Myofibrillar myopathy
8C77 – Ocular myopathy
8C7Y – Other specified primary disorders of muscles
8C7Z – Primary disorders of muscles, unspecified

Foundation entity

Malignant hyperthermia or hyperpyrexia – http://id.who.int/icd/entity/1397199211

Part of: 08: Diseases of the nervous system